| Q94022638 | 2016 TAJEV/Poster Presentation |
| Q26776336 | A review of the clinical performance of the Aptima HPV assay |
| Q37363392 | Differential Detection of Human Papillomavirus Genotypes and Cervical Intraepithelial Neoplasia by Four Commercial Assays |
| Q39338815 | HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer |
| Q47580645 | High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders |
| Q40116201 | Prevalence of Human Papillomavirus in Self-Taken Samples from Screening Nonattenders. |
| Q64056128 | Prevalence, correlates, and predictive value of high-risk human papillomavirus mRNA detection in a community-based cervical cancer screening program in western Uganda |
| Q40043990 | Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening. |
| Q37218627 | The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening |
| Q90168285 | Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation |